Jaya Naran, DO
Endocrinology, Diabetes & Metabolism · Hattiesburg, MSNPI 1316394448
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MS, where the typical reported total is $4,678.
Across 173 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$452
- Lilly USA, LLC$372
- Sanofi-aventis U.S. LLC$291
- Abbott$276
- Novo Nordisk$243
- Boehringer Ingelheim$162
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,103100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 29 | $452 |
| Lilly USA, LLC | 23 | $372 |
| Sanofi-aventis U.S. LLC | 14 | $291 |
| Abbott | 15 | $276 |
| Novo Nordisk | 14 | $243 |
| Boehringer Ingelheim | 11 | $162 |
| Xeris Pharmaceuticals, Inc. | 7 | $150 |
| Bayer | 7 | $125 |
| AbbVie | 8 | $121 |
| Dexcom, Inc. | 5 | $118 |
| Sequel Med Tech, LLC | 5 | $102 |
| Novartis | 6 | $99 |
| Insulet Corporation | 4 | $89 |
| Pfizer | 4 | $74 |
| Tandem Diabetes Care, Inc. | 4 | $68 |
| Radius Health, Inc. | 2 | $61 |
| Averitas Pharma Inc. | 2 | $51 |
| IBSA Pharma Inc. | 3 | $49 |
| Medtronic | 3 | $46 |
| RGH Enterprises LLC | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
How this compares
$3,103 in reported general payments places this provider in the 30th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 303 | $375,456 |
| JardianceEmpagliflozin | 273 | $268,838 |
| MounjaroTirzepatide | 100 | $137,398 |
| Tresiba Flextouch U-200Insulin Degludec | 110 | $116,174 |
| TrulicityDulaglutide | 69 | $79,002 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 106 | $77,229 |
| FarxigaDapagliflozin Propanediol | 79 | $69,775 |
| JanuviaSitagliptin Phosphate | 72 | $66,430 |
| Tresiba Flextouch U-100Insulin Degludec | 99 | $59,489 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 84 | $58,439 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 48 | $53,601 |
| TradjentaLinagliptin | 70 | $49,975 |
| Novolog FlexpenInsulin Aspart | 202 | $47,193 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $36,491 |
| VascepaIcosapent Ethyl | 59 | $28,121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $243 | $435,514380 claims |
| Boehringer IngelheimJardiance, Tradjenta | $162 | $318,813343 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $372 | $223,813194 claims |
| AbbVieSynthroid | $121 | $13,929189 claims |
| Sanofi-aventis U.S. LLCLantus | $291 | $7,64822 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $3,727496 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Hattiesburg
- Richard GallowayHattiesburg$109K
- James PowellHattiesburg$88K
- Aboorva Kambiliampatti SudhakarHattiesburg$1K
- Daniel McCallHattiesburg$1K
- Dana DaleHattiesburg$300
- Eric DyessJackson$885K
- Mark BorcheltGulfport$722K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.